<article id="tolerability_wAMD" class="slide" data-ag-name="Tolerability wAMD">
  <div class="tab-title">wAMD</div>
  <h2 class="slide-title">DEMONSTRATED TOLERABILITY<sup class="footnote-link">1</sup></h2>
   <p>Serious adverse reactions related to the injection procedure in the Phase III AMD trials have occurred in less than 1 in 1000 intravitreal injections (22&nbsp;of&nbsp;36,206&nbsp;injections) with either EYLEA<sup class="reg">&reg;</sup> or ranibizumab, and included endophthalmitis, cataract traumatic, increased intraocular pressure, retinal detachment, and vitreous detachment.</p>
  <div class="chart-header">Most common adverse reactions (ARs) reported in ≥5% of patients treated with EYLEA<sup class="reg">&reg;</sup><span class="asterisk">*</span></div>
  <div class="chart-img"><img src="content_EN/img/charts_t-wamd.png" /></div>
  <div class="keys"><div class="chart-key">* Combined safety data for VIEW 1 and VIEW 2 trials with up to 96 weeks’ exposure.</div></div>
</article>